Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 12/20 | 0.76 |
| ▸ | FNTB | P49356 | 12/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.62 |
| ▸ | PGGT1B | P53609 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL5511887 | 0.99 | FNTA (0.75) | FNTAFNTBCYP3A4PGGT1B | |
| SCHEMBL13529454 | 0.92 | FNTA (0.75) | FNTAFNTBCYP3A4PGGT1B | |
| SCHEMBL14013829 | 0.91 | FNTA (0.74) | FNTAFNTBCYP3A4PGGT1B | |
| SCHEMBL11947114 | 0.91 | FNTA (0.63) | FNTAFNTBCYP3A4PGGT1B | |
| SCHEMBL13573646 | 0.91 | FNTA (0.63) | FNTAFNTBCYP3A4PGGT1B | |
| SCHEMBL13573623 | 0.90 | FNTA (0.62) | FNTAFNTBCYP3A4 | |
| SCHEMBL11947148 | 0.90 | FNTA (0.62) | FNTAFNTBCYP3A4PGGT1B | |
| SCHEMBL11947185 | 0.90 | FNTA (0.62) | FNTAFNTBCYP3A4PGGT1B | |
| SCHEMBL5509171 | 0.90 | FNTA (0.73) | FNTAFNTBCYP3A4PGGT1B | |
| SCHEMBL13573641 | 0.90 | FNTA (0.73) | FNTAFNTBCYP3A4PGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100022467-A1 | ANTI-CANCER PHOSPHONATE ANALOGS | BOOJAMRA CONSTANTINE G | 2010-01-28 | — | — | US | disclosed |
| US-7645747-B2 | Improved pharmacokinetic properties, oral bioavailability; side effect reduction | GILEAD SCIENCES, INC. (US) | 2010-01-12 | — | — | US | disclosed |
| US-7452901-B2 | Anti-cancer phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2008-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022467-A1 | ANTI-CANCER PHOSPHONATE ANALOGS | PIK3CA, PHOSPHO1, PTEN | FNTA 663/4885FNTB 779/4885CYP3A4 4404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.